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Immunological memory—a defi  ning feature of 
adaptive immunity—is characterized by recall 
antibody responses that are more rapid, of a 
higher titer, and dominated by IgG (1, 2). Two 
factors contribute to this capability: an increased 
frequency of B cells and T cells with high af-
fi  nity antigen receptors, and the diff  erentiation 
of “memory cells” with heightened response 
capacity. Memory B cells have usually undergone 
an irreversible rearrangement of their Ig heavy 
chain genes (isotype switching), which removes 
the constant region exons encoding IgM and 
IgD B cell antigen receptors (BCRs) found on 
naive B cells and replaces them with constant 
region exons encoding membrane-bound IgG. 
Although isotype switching preserves antigen 
specifi  city, it substantially changes the transmem-
brane and cytoplasmic segments of the BCR. 
Membrane IgM and IgD have only three cyto-
plasmic amino acids and transmit signals into 
B cells through immunoreceptor tyrosine–
based activation motifs (ITAMs) in the cyto-
plasmic tails of an associated CD79a–CD79b 
heterodimer (3). Although IgG BCRs also as-
sociate and signal through CD79 heterodimers, 
each of the IgG subtypes has an extended, 
highly conserved cytoplasmic tail that has long 
been speculated to confer important signaling 
diff  erences (3). The nature of IgG BCR signal-
ing diff  erences nevertheless remains obscure.
Genetic manipulation in mice has estab-
lished that the IgG BCR tail is both necessary 
and suffi   cient for the dramatically enhanced 
  secretion of IgG that characterizes immuno-
logical memory. Truncation of the IgG cytoplas-
mic tail or the homologous tail in IgE through 
gene targeting in mice diminished the secretion 
of antigen-specifi  c IgG1 or IgE by >10–20-fold 
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Immunological memory is characterized by heightened immunoglobulin (Ig) G antibody 
production caused in part by enhanced plasma cell formation conferred by conserved 
transmembrane and cytoplasmic segments in isotype-switched IgG B cell receptors. We 
tested the hypothesis that the IgG tail enhances intracellular B cell antigen receptor (BCR) 
signaling responses to antigen by analyzing B cells from Ig transgenic mice with IgM recep-
tors or chimeric IgMG receptors containing the IgG tail segment. The IgG tail segment 
enhanced intracellular calcium responses but not tyrosine or extracellular signal–related 
kinase (ERK) phosphorylation. Biochemical analysis and crosses to CD22-defi  cient mice 
established that IgG tail enhancement of calcium and antibody responses, as well as mar-
ginal zone B cell formation, was not due to diminished CD22 phosphorylation or inhibitory 
function. Microarray profi  ling showed no evidence for enhanced signaling by the IgG tail 
for calcium/calcineurin, ERK, or nuclear factor κB response genes and little evidence for 
any enhanced gene induction. Instead, almost half of the antigen-induced gene response in 
IgM B cells was diminished 50–90% by the IgG tail segment. These fi  ndings suggest a novel 
“less-is-more” hypothesis to explain how switching to IgG enhances B cell memory responses, 
whereby decreased BCR signaling to genes that oppose marginal zone and plasma cell 
differentiation enhances the formation of these key cell types.
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during primary and secondary immunization (4, 5). This re-
sult shows that the tail is necessary for high-titer IgG memory 
responses. Conversely, addition of the IgG1 transmembrane 
and extended cytoplasmic segments to a hen egg lysozyme 
(HEL)–specifi  c IgM expressed in B cells of Ig gene transgenic 
mice (in place of the corresponding IgM tail) increased anti-
body titers and the formation of plasma cells by 10–50-fold 
during a primary immune response independent of any 
change in B cell precursor frequency or affi   nity (6). These 
complementary in vivo studies clearly established that the cy-
toplasmic tail of class-switched BCRs dramatically enhances 
B cell antibody responses, although the mechanism by which 
the tail enhances responses or changes BCR signaling remains 
to be defi  ned.
Recently, the extended IgG tail was found to increase 
BCR signaling to intracellular calcium and extracellular 
  signal–related kinase (ERK) by bypassing the inhibitory co-
receptor CD22 (7). CD22 is a 140-kD type I membrane 
protein on B cells, comprising extracellular Ig domains with 
lectin-like binding to sialic acid–modifi  ed proteins and an intra-
cellular domain containing three immunoreceptor tyrosine–
based inhibition motifs and two ITAM-like regions (8, 9). CD22 
is physically associated with not only IgM but also IgD or 
IgG (10, 11). After the engagement of BCR, CD22 is tyro-
sine phosphorylated (12, 13). Studies using Lyn-defi  cient 
mice suggested that Lyn is mainly involved in CD22 tyro-
sine phosphorylation after BCR cross-linking (14, 15). Phos-
phorylated CD22 recruits a negative regulator, Src homology 
domain 2–containing tyrosine phosphatase 1 (SHP-1) (16). 
Consequently, B cells from CD22-defi  cient mice exhibit an 
augmented calcium response upon BCR cross-linking. Strik-
ingly, CD22 phosphorylation failed to occur in B cell lym-
phoma cell lines expressing hapten-specifi  c IgG BCRs or 
chimeric IgMG receptors with IgG cytoplasmic tails, whereas 
CD22 was normally phosphorylated when IgM BCRs were 
expressed by the cells (7). The failure to phosphorylate CD22 
was accompanied by the failure to recruit SHP-1 and dra-
matically augmented calcium response and ERK activation. 
These studies have suggested that the heightened secretion of 
IgG in memory responses in vivo can be explained by the se-
questration of CD22 from IgG, resulting in a generalized in-
crease in BCR signaling to antigen. However, the extent to 
which in vivo antibody responses are negatively regulated by 
CD22 is unclear (17–20). Two groups showed a decreased 
proliferative response to BCR stimulation in CD22-defi  cient 
B cells, one group found no diff  erence, and a fourth study 
found hyperresponsiveness. One study showed augmented 
antibody formation upon T cell–dependent immunization of 
CD22-defi  cient mice, whereas others found a normal mag-
nitude of response. Hence, it is important to investigate 
whether or not the IgG tail confers heightened antibody 
  responses by exaggerating BCR signaling through a CD22 
bypass mechanism.
In this paper, we analyze the eff  ect of the IgG memory 
tail on BCR signaling in primary HEL antigen-specifi  c B 
cells, as well as the role of CD22 in the heightened antibody 
production conferred by the IgG tail. The data show that 
the IgG tail confers a higher Ca2+ response and augmented 
Figure 1.  IgG membrane tail BCR induces exaggerated Ca2+ infl  ux. 
RBC-depleted splenocytes from IgMG (continuous line) and IgM (dotted 
line) mice were labeled with 1 μM Indo-1 for 30 min at 37°C. The cells 
were counterstained with antibodies against B220 and CD21 for the fi  nal 
10 min of Indo-1 staining. The stained cells were fi  rst acquired for 30 s on 
an LSR fl  ow cytometer and then stimulated with anti-IgM F(ab’)2 antibody 
(A, 50 μg/ml; B, 5 μg/ml; and C, 0.5 μg/ml) or HEL (D, 5 μg/ml; and 
E, 0.5 μg/ml; both represent saturating concentrations), and the increase 
in intracellular calcium was revealed by the change in the mean Indo-1 
violet/blue ratio of the B220+CD21medium follicular B cell population. 
Data are representative of three experiments.JEM VOL. 204, April 16, 2007  761
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  antibody production in a CD22-independent manner. More-
over, the IgG tail does not enhance BCR signaling to ERK 
or to global gene expression, but instead half of IgM-induced 
genes are poorly induced by BCRs with the IgG tail. These 
fi  ndings reveal surprising qualitative diff  erences in BCR 
signaling conferred by the IgG tail, provide an explanation 
for the IgG tail–induced differences in immature and 
marginal zone B cell development, and suggest novel expla-
nations for the heightened antibody secretion in immunologi-
cal memory.
RESULTS
IgG membrane tail BCR induces exaggerated Ca2+ infl  ux
To analyze the eff  ect of the IgG tail on BCR signaling in 
  primary B cells, we took advantage of two well-matched 
Ig-transgenic strains of mice in which the B cells express iden-
tical BCRs with homogeneously high affi   nity for HEL, with 
the sole diff  erence being that in the IgM strain the BCR is 
native IgM, whereas in the IgMG strain the coding portions of 
the transmembrane and cytoplasmic exons are from IgG1 (21). 
Secreted IgM is identical in the two strains, as are all of the 
intronic and 3′ untranslated regions. We have previously shown 
that this precise substitution in the membrane tail of the BCR 
is suffi   cient to confer the in vivo antibody response–enhancing 
eff  ects seen in follicular B cells from a third set of Ig-transgenic 
strains expressing the native IgG1HEL BCR (6). Because the 
B cells in the IgM and IgMG mice are so closely matched in 
all respects other than the BCR tail, they provided an ideal 
experimental system to investigate how the IgG tail alters 
BCR signaling.
We fi  rst examined intracellular calcium mobilization after 
BCR stimulation. Cross-linking by F(ab')2 anti-IgM antibody 
induced a rapid calcium infl  ux, followed by a sustained eleva-
tion of intracellular calcium level in IgM B cells (Fig. 1, A–
C). IgMG B cells showed a slightly larger initial calcium spike 
in the high dose of stimulation (Fig. 1 A) and a higher sus-
tained calcium level in both high and low doses of stimula-
tion (Fig. 1, A–C) compared with IgM B cells. A similar 
trend was found for HEL stimulation (Fig. 1, D and E). Ex-
aggerated calcium response to BCR engagement was also 
consistently found in IgMG B cell responses to other BCR 
ligands (anti-kappa antibody or HEL conjugated to dextran), 
in immature B220low B cells from the bone marrow, and in 
B cells from IgG1 transgenic mice in which the entire con-
stant region is switched (unpublished data). The IgG tail thus 
enhances intracellular calcium response across a broad range 
of antigen receptor occupancies and degrees of receptor 
cross-linking.
In contrast to the exaggerated calcium response, however, 
the IgG tail did not alter tyrosine phosphorylation of total 
proteins and CD22, nor was there any increase in phosphory-
lation of ERK (Fig. 2). Cross-linking of BCR with F(ab')2 
anti-IgM antibody, at an optimal concentration that caused a 
marked diff  erence in intracellular calcium, induced compara-
ble patterns and magnitudes of tyrosine phosphorylation of 
total cellular proteins in IgM and IgMG B cells (Fig. 2 A). 
CD22 was tyrosine phosphorylated in IgM and IgMG B cells 
with similar kinetics and extent in response to F(ab')2 
anti-IgM or HEL stimuli that caused heightened calcium re-
sponses (Fig. 2 B and Fig. S1, available at htttp://www.jem
.org/cgi/content/full/jem.20061923/DC1). ERK activation 
upon BCR ligation was measured by intracellular staining 
with a phospho-ERK–specifi  c antibody. Phosphorylation of 
ERK was detected clearly after BCR ligation with F(ab')2 
anti-IgM or HEL with identical kinetics and magnitude in 
IgM and IgMG B cells (Fig. 2 C and not depicted). The induc-
tion of ERK phosphorylation was almost completely inhibited 
by the mitogen-activated protein (MAP) kinase/ERK kinase 
(MEK) inhibitors PD98059 or U0126 (Fig. 2 D), indicating 
the specifi  city of the antibody used for the experiment. These 
results indicate that the IgG tail does not dramatically alter 
the broad pattern of BCR signaling in primary B cells and 
that the eff  ect on calcium appears quite specifi  c.
IgG tail BCR interferes with the induction of antigen 
response genes
To obtain a global view of the extent to which the IgG tail 
changes BCR signaling to antigen, we employed a microar-
ray strategy previously used to reveal qualitative diff  erences in 
Figure 2.  IgG membrane tail does not alter tyrosine phosphoryla-
tion of CD22 or ERK phosphorylation. Splenocytes from IgM and IgMG 
transgenic mice were stimulated with 50 μg/ml anti-IgM F(ab’)2. Total 
cellular proteins (A) or immunoprecipitated CD22 (B) were fractionated 
by SDS-PAGE and Western blotted with antiphosphotyrosine antibody 
(A and B, top) or anti-CD22 antibody (B, bottom). The ratios of phosphory-
lated CD22 to total CD22 are indicated. (C and D) Mean fl  uorescence in-
tensity (MFI) of permeabilized B220+CD21mediumCD23+ follicular B cells 
stained by fl  ow cytometry for phosphorylated ERK either (C) at the indi-
cated times after stimulation with 50 μg/ml anti-IgM F(ab’)2 or (D) in 
unstimulated (−) versus stimulated (+) cells after 2 min in the presence 
of MEK inhibitors PD98059, U0126, or DMSO as diluent controls. Data are 
representative of two experiments.762  EFFECTS OF IGG TAIL ON B CELL ANTIGEN RECEPTOR SIGNALING | Horikawa et al.JEM VOL. 204, April 16, 2007  763
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BCR signaling in primary HEL-specifi  c IgM/IgD B cells 
caused by clonal anergy or by pharmacological inhibition of 
calcium, calcineurin, or MEK/ERK (22). To eliminate any 
contribution from the serum response genes observed previ-
ously when we compared profi  les of fresh ex vivo B cells 
with 1-h cultured cells (23), IgM and IgMG B cells were 
stimulated in vivo by intraperitoneal injection of a dose of 
HEL antigen that—like the concentrations of HEL used in 
vitro—rapidly saturated antigen receptors and gave robust, 
synchronous CD69 and CD86 induction on Ig-transgenic 
B cells (unpublished data). Spleen cell suspensions were pre-
pared 1 h later, follicular B cells were sorted as CD21medium 
and CD23+, and mRNA was purifi  ed immediately. Multiple 
independent sorting experiments were performed from stim-
ulated and unstimulated control IgM and IgMG mice, and 
the mRNA from independent experiments was combined 
into one or the other of two independent pools for each of 
the four conditions. Labeled cRNA from each of the eight in-
dependent pools was analyzed on Aff  ymetrix Murine Genome 
Array U74Av2 chips.
We initially focused our analysis on the set of pharmaco-
logically profi  led BCR response genes previously defi  ned in 
naive IgM/IgD B cells stimulated by HEL for 1 h in vitro. 
This set comprised 35 HEL-induced and 21 HEL-repressed 
genes that are also tiled on the U74Av2 chip used in this 
study. After 1 h of in vivo HEL stimulation of IgM B cells, 
34 out of the 35 HEL-induced genes were reproducibly in-
creased compared with unstimulated IgM B cells, and 15 out 
of the 21 HEL-repressed genes were decreased (Fig. 3 C and 
Fig. S2, available at htttp://www.jem.org/cgi/content/full/
jem.20061923/DC1). Examining the response of IgM and 
IgMG B cells, only 3 out of the 35 HEL-induced genes (Fos, 
Ptpn8, and Cebpb) and 0 out of the 21 HEL-repressed genes 
(Fig. S2 D) showed any evidence of increased signaling by the 
IgG tail, and these eff  ects were subtle (Fig. 3 C). 19 out of the 
34 HEL-induced genes in IgM B cells were either equally in-
creased by HEL signaling through IgMG (Egr1, Tis11, Tis11b, 
Dusp2, Rp105, Evi2, 4F2, IL1r2, and Dusp1) or were slightly 
less well induced in IgMG B cells (Nab2, MacMARCKS, 
Stra13, Egr2, Myc, AhR, Gem, Bcl2a1b/A1, Fosb, and Cd72). 
These included established reporters for the ERK pathway 
(Egr1, Nab2, and Dusp2/Pac1), the calcium–nuclear factor of 
activated T cells pathway (Egr2 and CD72), and the NF-κB 
pathway (c-myc and A1/Bcl2a1b). All 15 of the HEL-repressed 
genes in IgM cells were equally decreased in IgMG cells 
(Fig. S2 D). These data confi  rm that the IgM and IgMG cells 
had been equally stimulated by antigen, and that the IgG tail 
does not cause a global increase in BCR signaling.
In contrast, 12 out of the 34 IgM HEL response genes 
were poorly induced in IgMG cells, attaining levels that 
were only 10–50% of those in IgM cells (Irf4, uPAR, Mafk, 
Nur77, Gfi  1, Gadd153, Myd116, Snk, Tis7, Atf3, Ccl3, and 
Ccl4). The poorly induced genes did not correspond to any 
particular BCR signaling pathway, nor did they correspond 
to genes that are poorly induced in anergic B cells. For ex-
ample, although Ccl3, Ccl4, and Myd116 were previously 
shown to be completely calcium/calcineurin dependent and 
not induced in anergic B cells (22), other genes with this 
profi  le were induced in IgMG B cells (e.g., Tis11b, Evi2, 
Ptpn8,  MacMARCKS, and A1/Bcl2A1b). Similarly, mafK 
was poorly induced in IgMG cells and corresponds to a sub-
set that is MEK dependent but blocked in anergic B cells, 
implying a requirement for ERK signaling plus one of the 
blocked signaling pathways in anergic cells, such as NF-κB 
or c-Jun N-terminal kinase. However, other genes in this 
category are induced normally (Tis11b and MacMARCKS). 
Based on these data, we conclude that a chief eff  ect of the 
IgG tail is to diminish BCR signaling for a selected subset of 
the normal response, but this qualitative change does not 
correspond to any known pharmacological and functional 
BCR signaling profi  le.
Because this analysis was limited to response genes de-
fi  ned previously in IgM/IgD B cells, we next extended it 
globally to include all of the genes on the U74 microarray 
and identifi  ed those showing a reproducible HEL response in 
either IgM or IgMG B cells. HEL stimulation increased the 
expression of 265 genes in IgM B cells, but of these only 114 
were substantially increased in IgMG B cells, thus extending 
the observations made with the smaller set (Fig. 3, A and D). 
Among the additional genes that were strongly induced in 
IgM B cells but either not induced or only very poorly in 
IgMG B cells were genes encoding chemokine receptors 
Ccr9 and Ccr7, the cell surface lectin Cd83, the NF-κB sig-
naling regulator IκBβ, and the transcription factor Atf4. Also 
consistent with this evidence, only 13 genes showed evidence of 
greater induction in IgMG B cells compared with IgM cells, 
Figure 3.  The IgG tail does not confer an enhanced gene expres-
sion response but blunts a subset of the IgM response. IgM and 
IgMG follicular B cells were stimulated (S) with 5 mg HEL for 1 h in vivo 
or were unstimulated (U) and then fl  ow sorted based on CD21 and 
CD23 staining. Purifi  ed RNA from multiple experiments was combined 
into two independent pools for each stimulation condition and analyzed 
on Affymetrix U74A microarrays. Increased and decreased genes were 
defi  ned as those with more than twofold induction or suppression, 
respectively, and present in both stimulated samples or in both unstim-
ulated samples, respectively. (A and B) Schematic comparing the total 
number and overlap of genes with increased (A) or decreased (B) 
expression upon antigen stimulation. The sizes of squares indicate the 
number of genes. (C) Expression of genes previously defi  ned as induced 
by HEL stimulation of naive IgM/IgD B cells (references 22, 23). The left 
end of the line represents the signal of gene expression in unstimulated 
cells; the right end represents the same in cells stimulated with HEL 
for 1 h. Each line represents one experiment. Blue line (crosses), IgM 
B cells; red line (circles), IgMG B cells. (D and E) Hierarchical clustering 
on all induced (D) or suppressed (E) genes. Red denotes the increased 
expression relative to the average of all samples, whereas green denotes 
decreased expression relative to the average. Black denotes values 
near the average of all samples. Note that approximately half of the 
response genes in stimulated IgM B cells are induced to lower levels in 
IgMG B cells.764  EFFECTS OF IGG TAIL ON B CELL ANTIGEN RECEPTOR SIGNALING | Horikawa et al.
and these eff   ects were marginal for most, except Akap9, 
Ddx6, and 4930517K11Rik, where the IgM response ap-
peared to be in the opposite direction (Fig. S2 B). These re-
sults indicate that the IgG tail does not increase BCR signaling 
for gene expression, and establish that its predominant eff  ect 
is a graded decrease aff  ecting a substantial subset of response 
genes that do not match currently established BCR signaling 
pathways in any straightforward manner.
IgG membrane tail increases calcium fl  ux and antibody 
production independent of CD22
We next crossed CD22-defi  cient mice with IgM or IgMG 
transgenic mice to test the possibility that diff  erences in CD22 
activity might explain the heightened calcium response to 
antigen in B cells with IgG tail BCRs or the heightened 
T cell–dependent antibody response in vivo.   CD22 defi  ciency 
caused a slight decrease in BCR density on follicular B cells 
of IgM and IgMG transgenic mice ( unpublished data). Con-
sistent with published data in nontransgenic mice (17–20), 
intracellular Ca2+ elevation was slightly but consistently in-
creased in CD22-defi  cient IgM and IgMG B cells compared 
with CD22-expressing counterparts over a range of anti-IgM 
F(ab')2 antibody concentrations (Fig. 4, A and B). The eff  ect 
of CD22 defi  ciency was subtle compared with the eff  ect of 
the IgG tail, but this subtle enhancement of calcium response 
was also caused by CD22 defi  ciency in IgMG B cells, indi-
cating that CD22 has a comparable inhibitory eff  ect on sig-
naling by BCRs with the IgG tail. Moreover, when IgM and 
IgMG B cells were stimulated with HEL antigen, there was 
no exaggeration of intracellular calcium response caused by 
CD22 defi  ciency, whereas the IgG tail again markedly en-
hanced calcium responses (Fig. 4, C and D). The absence of any 
eff  ect of CD22 defi  ciency on Ca2+ response to HEL antigen 
was also observed in IgMD B cells (i.e., B cells coexpressing 
IgM and IgD) (24) (Fig. S3, available at htttp://www.jem
.org/cgi/content/full/jem.20061923/DC1). Thus, the IgG tail 
enhances BCR-induced calcium responses via a mechanism that 
does not involve diff  erences in the activity of CD22.
Because the most dramatic eff  ect of the IgG tail is ob-
served in T cell–dependent antibody responses in vivo, where 
it increases B cell diff  erentiation into plasma cells approxi-
mately 50-fold (6), we tested whether or not this was ex-
plained by diff  erential action of CD22. Equal numbers of 
HEL-binding IgM or IgMG B cells, expressing or lacking 
CD22, were adoptively transferred into nonirradiated 
C57BL/6 mice, and the recipient mice were immunized with 
lysozyme in adjuvant. The concentration of HEL-reactive 
IgMa in the serum was measured 10 d after immunization 
(Fig. 5). As previously observed (6), CD22+ IgMG B cells 
produced 10–50 times more antibody than CD22+ IgM 
B cells. CD22 defi  ciency did not increase antibody secretion 
by IgM or IgMG B cells, and there was an equally large dif-
ference between responses from IgM and IgMG B cells on 
the CD22-defi  cient background, establishing that the IgG 
tail increases antibody responses by a mechanism that is inde-
pendent of CD22.
CD22 defi  ciency does not suppress marginal zone B cell 
differentiation when the BCR carries the IgG tail
Diff  erentiation of splenic marginal zone B cells has been sug-
gested to require a lower level of BCR signaling compared 
with diff  erentiation of follicular B cells (25),   although other 
studies indicate that greater BCR signaling   correlates with 
marginal zone cell diff  erentiation (26, 27). Enhancement of 
BCR signaling caused by CD22 defi  ciency thus represents 
one explanation for the suppressed formation of marginal 
Figure 4.  IgG membrane tail evokes an augmented Ca2+ response 
independent of CD22. RBC-depleted splenocytes from mice of the indi-
cated genotypes were labeled with 1 μM Indo-1 for 30 min at 37°C. 
(A and B) The cells were counterstained with antibodies against B220 and 
CD21 for the fi  nal 10 min of Indo-1 loading. The stained cells were at fi  rst 
acquired for 30 s and then stimulated with the indicated concentrations 
of anti-IgM F(ab’)2 antibody (A, 5 μg/ml; and B, 0.5 μg/ml). Lines show 
the mean Indo-1 ratio in B220+CD21medium cells. Data from one out of 
three independent experiments are shown. (C and D) Indo-1–loaded cells 
stained with antibody against B220 were simulated with the indicated 
concentrations of HEL conjugated to PE (HEL-PE; C, 5 μg/ml; and D, 0.5 
μg/ml), and the Indo-1 ratio was measured on gated HEL+ B220+ cells.JEM VOL. 204, April 16, 2007  765
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zone but not follicular B cells in CD22-defi  cient  mice 
(20, 28). Thus, we examined diff  erentiation of HEL-specifi  c 
B cells into these two subsets in CD22+/− and CD22-defi  -
cient IgM and IgMG mice by staining for CD21/CD23 or 
CD21/CD1d (Fig. 6). In CD22+/− IgM transgenic mice, 
4.69 ± 0.97% of HEL-binding B cells were marginal zone 
B cells. This population was decreased 10-fold (0.48 ± 032%) 
in CD22-defi  cient IgM transgenic mice, consistent with pub-
lished data in mice with a polyclonal BCR repertoire. As 
noted previously in IgG and IgMG IgHEL transgenic mice 
(6, 21), exchange of the IgM tail for the IgG tail dramatically 
increased the formation of marginal zone B cells to account 
for 39.4 ± 7.4% of HEL-binding B cells in CD22+/− IgMG 
animals. Remarkably, CD22 defi   ciency had no eff  ect  on 
IgMG B cell diff  erentiation into marginal zone cells, as these 
still accounted for 36.4 ± 7.3% of HEL-binding B cells in 
CD22−/− IgMG animals. As discussed in the next section, 
the enhanced formation of marginal zone B cells even in the 
absence of CD22 is consistent with lower signaling by BCRs 
with the IgG tail.
D  I  S  C  U  S  S  I  O  N 
The experiments described in this paper reveal striking quali-
tative diff  erences in BCR signaling and responses to antigen 
that are conferred solely by exchanging the transmembrane 
region and short cytoplasmic tail of IgM for the correspond-
ing regions of IgG1, which contain a longer cytoplasmic tail 
that is highly conserved between IgG subtypes and species. 
It has previously been shown that the IgG tail segment is 
necessary for high-titer IgG secretion in a polyclonal repertoire 
(4, 5) and suffi   cient to confer the dramatic enhancement in 
plasma cell formation and T cell–dependent antibody secre-
tion that is observed when the entire constant region is 
switched from IgM to IgG1 (6). Logically it might be ex-
pected that the IgG tail enhances antibody responses by 
increasing BCR signaling to proimmunity pathways, either 
by recruiting additional signaling components or by avoid-
ing inhibitory countersignals such as CD22 and SHP-1. The 
data in this study show that the IgG tail does enhance intra-
cellular calcium responses (Fig. 1), but this is not because of 
any diff  erence in activity of the inhibitory receptor CD22 
(Fig. 2 and Fig. 4), nor is it refl  ected in a general increase in 
protein tyrosine phosphorylation, ERK signaling, or induc-
tion of gene expression in the nucleus (Fig. 2 and Fig. 3). At 
the level of gene expression responses induced by antigen, 
the chief eff  ect of the IgG tail is to selectively decrease a large 
subset of the response (Fig. 3). This qualitatively diminished 
signaling for gene expression is paralleled by the eff  ects of the 
IgG tail on diff  erentiation into marginal zone B cells, which 
is enhanced by the tail and no longer blocked when BCR 
signaling is exaggerated by CD22 defi  ciency. These fi  ndings, 
together with complementary data from studies of IgG 
knock-in mice by Waisman et al. (see Waisman et al. [29] on 
p. 747 of this issue), raise an alternative hypothesis for the 
action of the tail, namely that it qualitatively alters BCR sig-
naling to diminish gene expression responses that normally 
oppose marginal zone diff  erentiation, extrafollicular B cell pro-
liferation, and diff  erentiation into plasma cells.
In this study, we found that the heightened antibody pro-
duction in memory B cells is not caused by a general increase 
in BCR signaling secondary to sequestration of the inhibitory 
receptor CD22 from BCRs with the IgG tail. Consistent 
with published data in lymphoma cell lines (7) and with the 
accompanying study of primary B cells in IgG knock-in mice 
(29), the IgG tail increased the intracellular Ca2+ response of 
primary follicular or immature B cells to antireceptor anti-
bodies or to antigen (Fig. 1 and Fig. 4). However, based on 
the data from crossing CD22-defi  cient mice to IgMG or IgM 
transgenic mice (Fig. 4), we conclude, as do Waisman et al. 
(29), that in primary B cells the IgG tail enhances intracellular 
calcium responses through a route that is unrelated to CD22. 
Equally, the data in Fig. 5 showed that the dramatic enhance-
ment of T cell–dependent antibody responses conferred by 
the IgG tail was unrelated to CD22. These results are consis-
tent with the fi  ndings of three groups out of four that show 
normal thymus- dependent antibody responses in CD22-
  defi  cient mice (17, 19, 20), although one group has reported 
augmented thymus-dependent response (18). It is worth not-
ing that our previous sorting experiments established that the 
enhanced antibody responses by IgMG and IgG B cells are 
derived from follicular cells and not from the expanded sub-
set of marginal zone B cells (6).
What has brought about the discrepancy between 
Wakabayashi et al. (7) and the fi  ndings in this study and 
Waisman et al. (29)? Wakabayashi et al. studied an IgG2a/λ 
Figure 5.  IgG membrane tail increases antibody production inde-
pendent of CD22. 5 × 105 HEL-binding splenic B cells from IgMG or 
IgM transgenic donors of the indicated CD22 genotypes were adoptively 
transferred into nonirradiated C57BL/6 mice, and the recipient mice were 
immunized with HEL in CFA. The concentration of anti-HEL IgMa antibody 
10 d after immunization was measured in the serum of individual recipi-
ent mice (circles) by ELISA. Data are representative of three separate 
experiments. Signifi  cant differences were determined by the Mann-Whitney 
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BCR specific for the hapten NP expressed mostly in the 
B lymphoma line K46 and stimulated with NP-BSA antigen. 
It is unlikely that this discrepancy can be explained by the 
diff   erence in isotypes, because the cytoplasmic regions of 
IgG2a and IgG1 have high sequence similarity (3). In terms 
of BCR stimulation, we used two diff  erent types of stimu-
lants, anti-IgM antibody or the antigen HEL for the CD22 
tyrosine phosphorylation experiment, resulting in similar 
results. They used other B cell lines, such as WEHI-279, 
BAL17, and A20 and even LPS-stimulated primary B cells, as 
well as K46. However, we speculate that it can be most likely 
caused by the diff  erence between cell lines and primary cells 
or a specifi  c characteristic of the NP-reactive BCR.
How does the IgG tail enhance the antigen-induced cal-
cium response, and how might this relate to the enhanced 
formation of plasma cells? A recent report showed that CD22 
attenuated calcium signaling by physical association with 
plasma membrane calcium–ATPase in a BCR stimulation–
dependent way (30). However, the comparison of CD22-
defi  cient and wild-type B cells in this paper establish that the 
exaggerated calcium response conferred by the IgG tail can-
not be caused by an eff  ect of CD22 on plasma membrane 
calcium–ATPase. It is conceivable that in primary B cells, the 
IgG tail might enable the BCR to escape calcium-attenuating 
eff  ects of coreceptors other than CD22, or it may enhance 
the open state of other Ca2+ channels, such as calcium release–
activated Ca2+ (CRAC) channels, voltage-gated L-type Ca2+ 
channels, or transient receptor potential channels. The en-
hanced calcium response caused by the IgG tail is neverthe-
less not refl  ected in the profi  le of genes induced by antigen. 
For example, the HEL-induced genes Egr2, Cd72, Tis11b, 
Ccl4, Ccl5, Ptpn8, MacMARCKS, Myd116, Ebi2, A1, and 
Evi2 are all calcium/calcineurin dependent (22), yet only one 
of these genes (Ptpn8) shows marginal evidence of increased 
induction in IgMG cells, whereas the rest are either induced 
equally or much less. Instead of enhancing the induction of 
calcium response genes, it is possible that the main eff  ect of the 
enhanced calcium is to activate inhibitory signaling circuits.
We also found almost no diff  erence in ERK phospho-
ry  lation between control and CD22−/− IgM/IgD B cells 
Figure 6.  CD22 defi  ciency suppresses IgM but not IgMG marginal 
zone B cell differentiation. Splenocytes were stained with HEL and com-
binations of antibodies against CD21/CD23/HyHEL9/B220 (A and B) or 
CD21/CD1d/HyHEL9/B220 (C and D). (A and C) The displayed profiles 
are gated on B220+ HEL-binding cells, and the percentage of B220+ 
HEL-binding cells in each window is shown. (B and D) Percentages of 
HEL-binding B cells in the marginal zone subset in individual mice (circles). 
Signifi  cant differences, as determined by the Student’s t test, are indicated.JEM VOL. 204, April 16, 2007  767
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(unpublished data), which is in line with reports using 
CD22−/− mice that showed normal ERK activation (31, 32). 
Analysis of BCR signaling to the MAP kinase ERK and the 
global pattern of antigen-induced genes are inconsistent with 
the hypothesis that the IgG tail causes a generalized enhance-
ment of BCR signaling. In primary B cells with IgM or 
IgMG BCRs, engagement of these receptors induced com-
parable ERK phosphorylation (Fig. 2) and comparable in-
duction of the Egr1 and Nab2 genes, which are targets of 
ERK signaling in the nucleus (22). Examining the global pat-
tern of genes that are induced by HEL also clearly indicates 
that the IgG tail enhances very few gene responses, whereas 
it diminishes induction of almost 50% of the response genes.
The diminished induction of BCR response genes caused 
by the IgG tail may explain the dramatic increase in marginal 
zone B cells in IgMG and IgG mice in this paper and in IgG 
knock-in mice in the study by Waisman et al. (29). Several 
lines of evidence indicate that marginal zone B cell diff  eren-
tiation is favored by genetic alterations that diminish BCR 
signaling strength compared with follicular B cell diff  eren-
tiation (25), although evidence to the contrary also exists 
(26, 27). Consistent with this idea, CD22 defi  ciency selec-
tively eliminates marginal zone B cells with a polyclonal 
BCR repertoire (20, 28) or with HEL-specifi  c IgM BCRs 
(Fig. 6). The 900% increase in marginal zone B cells caused 
by the IgG tail, as well as the lack of any reduction when 
combined with CD22 defi  ciency despite heightened calcium 
signaling, may refl  ect poor induction by the IgG tail of BCR 
response genes that oppose marginal zone diff  erentiation. In 
this respect, it is noteworthy that the chemokine receptor 
CCR7 failed to be induced by antigen in IgMG cells (Fig. 3 D). 
Induction of CCR7 by BCR engagement attracts IgM/IgD 
B cells away from the marginal zone and into the T-zone, 
whereas B cells that lack CCR7 are attracted toward the mar-
ginal zone (33, 34). Because marginal zone diff  erentiation 
also depends on Notch2 signaling, it is also possible that the 
qualitative changes in BCR signaling caused by the IgG tail 
may directly or indirectly enhance Notch signaling, although 
this will need to be explored in future studies.
The studies by Waisman et al. (29) on IgG knock-in 
mice are also consistent with diminished BCR signaling for 
immature B cell diff  erentiation compared with IgM. They 
fi   nd that IgG-expressing cells progress ineffi   ciently  from 
pro– to pre–B cell/immature B cell stages, which could re-
fl  ect too little or too much BCR signaling. Under competi-
tive conditions, a low proportion of IgG-expressing B cells 
develop in the bone marrow compared with IgM-expressing 
cells, but this is reversed in the presence of an ITAM dele-
tion in the Igα/CD79a cytoplasmic tail (29). Because the 
CD79a deletion dramatically enhances BCR signaling (35), 
the fact that it improves maturation of IgG-bearing cells 
while diminishing maturation of IgM-bearing cells indicates 
that IgG signaling for immature B cell maturation is nor-
mally suboptimal.
These fi  ndings suggest a novel “less-is-more” hypothesis 
to explain the heightened antibody production conferred by 
the IgG tail, whereby decreased signaling to a subset of BCR 
response genes increases plasma cell formation. Like the in-
hibitory eff  ect of CCR7 induction on migration toward the 
marginal zone, some of the poorly induced genes in IgMG 
B cells may be inhibitory for B lymphoblast survival or dif-
ferentiation into plasma cells. For example, the poorly in-
duced chemokine ligand CCL4 (also know as macrophage 
infl  ammatory protein–1B) attracts CD4+CD25+ regulatory 
T cells to IgM-activated B cells (36), and these cells are po-
tent inhibitors of B cell antibody production (37, 38). The 
qualitative changes in IgG tail BCR signaling defi  ned here—
in particular the evidence that it diminishes a subset of 
the cellular response rather than enhancing it, as had been 
predicted—may not only change views of how isotype switch-
ing to IgG enhances memory responses but also may have 
ramifi  cations for the control of self-reactive B cells.
MATERIALS AND METHODS
Mice. C57BL/6 transgenic mouse strains expressing the IgM or IgMG 
BCR-recognizing HEL MM4 (39) or MG2 (21), respectively, were used in 
this paper. They were backcrossed on the B10.BR:RAG1−/− background 
and used for biochemical experiments. cd22−/− mice (provided by E.A. 
Clark, University of Washington, Seattle, WA) were previously described 
elsewhere (19) and were crossed with C57BL/6 MM4 and MG2 strains to 
generate IgM or IgMG Ig transgenic mice in a CD22−/− background. All 
mice were maintained and treated in accordance with principles outlined by 
the Australian National University Animal Experimentation Ethics Com-
mittee and the current Australian Code of Practice for the Care and Use of 
Animals for Scientifi  c Purposes.
Flow cytometric analysis and intracellular staining. Single-cell suspensions 
(106 cells) were made from spleens and blocked with FACS-staining buff  er 
(PBS containing 2% FCS and 0.05% sodium azide) and anti-CD16/CD32 
antibody (clone 2.4G2; BD Biosciences). After washing, the cells were 
stained with combinations of antibodies. Data were acquired with a FACS-
Calibur (Becton Dickinson) and analyzed with CellQuest (Becton   Dickinson) 
or FlowJo (TreeStar Inc.) software. For the staining for lysozyme binding, 
splenocytes were fi  rst treated with 1 g/ml HEL and then stained with Tri-
Color-conjugated HyHEL9. The following antibodies were used: FITC-
conjugated anti-CD21 (7G6), anti-B220 (RA3-6B2), PE-conjugated anti-IgMa 
(DS-1), anti-CD1d (1D1), anti-CD23 (B3B4), and allophycocyanin-conjugated 
anti-B220 (RA3-6B2; all obtained from BD Biosciences).
For the intracellular staining of phospho-ERK, unstimulated or stimu-
lated splenocytes were fi  xed with 2% paraformaldehyde at room temperature 
for 15 min (40, 41). Cells were centrifugated, resuspended in 100 μl PBS, 
and permeabilized with 900 μl of ice-cold methanol. After washing with the 
FACS staining buff  er, the cells were stained with anti–phospho-p44/42 
MAP kinase (Thr202/Tyr204) antibody (Cell Signaling Technology), 
followed by Cy5-conjugated Affi   niPure F(ab')2 fragment donkey anti–
rabbit IgG (H+L; Jackson ImmunoResearch Laboratories). MEK inhibitors 
PD98059 and U0126 (both obtained from Calbiochem) were used for 
checking the specifi  city of the phospho–MAP kinase antibody at a concen-
tration of 10 μM.
Calcium measurement. Splenocytes were incubated with 1μM Indo-1 
AM (Invitrogen) in RPMI 1640 containing 10 mM Hepes and 2% FCS at 
37°C for 30 min. After washing the loaded cells, they were stained with 
FITC-conjugated anti-CD21 and PE-conjugated anti-B220 antibodies or 
FITC-conjugated anti-B220 antibody for HEL-PE stimulation at room tem-
perature for 10 min. HEL concentrations >0.5 μg/ml were used in vitro, 
because these rapidly achieved receptor saturation and gave robust, synchro-
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intracellular Indo-1 was monitored using a FACS LCR system (Becton 
Dickinson) and analyzed by FlowJo software.
Microarray analysis. Mice bearing IgM or IgMG BCR were left unstimu-
lated or stimulated with an intraperitoneal injection of 5 mg of HEL. This 
dose of soluble HEL (which has a short plasma half-life) was chosen because 
it results in receptor-saturating concentrations of circulating HEL for several 
hours, and in systematic dose–response studies it gave robust, synchronous 
CD69 and CD86 responses by Ig transgenic cells in vivo. Comparable re-
ceptor saturation and CD69 and CD86 responses were induced by 0.5 μg/ml 
HEL or greater in vitro, which is the concentration used in the biochemical 
experiments and our previous microarray experiments (22). It is worth not-
ing that CD69 is itself an ERK response gene (42, 43). 1 h later, spleen cell 
suspensions were prepared on ice and stained with anti-CD21–FITC and 
anti-CD23–PE, the follicular B cell fraction was purifi  ed on a FACS DIVA 
sorter and held on ice during sorting, and an aliquot was reanalyzed to confi  rm 
purity  >90% and centrifuged and lysed in TRIzol (Invitrogen). Total 
RNAs were purifi  ed, quantifi  ed, and pooled from multiple sorting experi-
ments (unstimulated IgM 1, two mice; unstimulated IgM 2, four mice; 
stimulated IgM 1, four mice; unstimulated IgM 2, two mice; unstimulated 
IgMG 1, fi  ve mice; unstimulated IgMG 2, six mice; stimulated IgMG 1, 
eight mice; and unstimulated IgMG 2, six mice). cRNA was generated ac-
cording to the Aff  ymetrix protocol. Fragmented cRNA were hybridized 
with mouse U74Av2 chip sets. The data were analyzed after normalization 
using Microarray Suite 5.0 (Aff   ymetrix). Clusterings of gene expression 
were performed with Genes@Work (IBM Research) (44). Microarray data 
have been deposited in the National Center for Biotechnology Information 
Gene Expression Omnibus under accession no. GSE7218 and sample nos. 
GSM173561–GSM173569.
Immunization and ELISA. The same number of HEL-binding B cells 
(0.5–1 × 106 cells) were adoptively transferred to unirradiated C57BL/6 re-
cipient mice. The recipient mice were intraperitoneally immunized with 
100 μg HEL in CFA. This dose was used because it induces optimal anti-
body responses in vivo. The sera were obtained 10 d after immunization, 
and the titers were measured by HEL-specifi  c ELISA. Lysozyme-binding 
IgM were captured by HEL-coated plates and treated with biotinylated allo-
specifi  c anti-IgMa (clone DS1; BD Biosciences), followed by streptavidin-
peroxidase (Sigma-Aldrich).
Western blotting and immunoprecipitation. Total splenocytes or puri-
fi  ed splenic B cells were stimulated with anti-IgM F(ab')2 or HEL for the 
times indicated in the fi  gures. The stimulated cells were lysed with TNE 
buff  er (1% [wt/vol] nonident P-40, 20 mM Tris-HCl [pH 8], 0.1 mM 
sodium orthovanadate with complete protease inhibitor; Roche). The lysates 
were centrifugated to remove insoluble debris. After an addition of 3× 
sampling buff  er, NP-40–soluble total proteins were subjected to SDS-PAGE. 
For immunoprecipitation of CD22, the lysates were precleared with protein 
G–sepharose (GE Healthcare), and CD22 was immunoprecipitated with 
anti-CD22 antibody (clone Cy34.1, BD Bioscience; or clone 2D6, Chemicon) 
and protein G–sepharose. After extensive washing, the immune complexes 
were fractionated by SDS-PAGE. The membranes were stained with an-
tiphosphotyrosine (clone 4G10; Upstate Biotechnology), followed by horse-
radish peroxidase–conjugated anti–mouse IgG (MP Biomedicals). The 
antibody-reacted bands were visualized with Western Lightning Chemilu-
minescence Reagent (PerkinElmer). After stripping, the membranes were 
stained with goat anti–mouse Siglec-2 (CD22) antibody (R&D Systems), 
followed by horseradish peroxidase–conjugated anti–goat antibody (Jackson 
ImmunoResearch Laboratories). The band intensities were measured by 
  ImageJ software (National Institutes of Health).
Online supplemental material. Fig. S1 shows tyrosine phosphoryla-
tion of CD22 in response to anti-IgM F(ab’)2 or HEL stimulation in IgM 
versus IgMG B cells. Fig. S2 shows additional expression patterns of gene 
induction or decrease from the microarray experiments. Fig. S3 shows 
intracellular calcium responses in CD22-defi  cient or wild-type IgMD 
B cells. Online supplemental material is available at htttp://www.jem.org/
cgi/content/full/jem.20061923/DC1.
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